Integrated approach to therapy and prevention of recurrences bacterial vaginosis in women of reproductive age with overweight and obesity

Abstract

The aim of the study was to evaluate the clinical efficacy of an integrated approach to therapy and prevention of relapse of bacterial vaginosis in women of reproductive age with overweight and obesity. We examined 60 women of reproductive age (19–39 years) with overweight and obesity (BMI+30±4.2) and a verified diagnosis of recurrent bacterial vaginosis (real-time PCR, diagnostic system Femoflor–16). The effectiveness of treatment of bacterial vaginosis in overweight and obese women was 94.0% due to the rapid elimination of the pathogen by a single dose of 2 g of the drug group 5-nitroimidazoles Secnidox and macrolide 16-membered antibiotic with bactericidal mechanism Doramycin (World Medicine, United Kingdom). Combination prolonged therapy with the multi-strain probiotic Brevelac and the natural drug Reitoil increased the remission period of bacterial vaginosis to 6 months in 91.0% of this group of patients. Keywords: bacterial vaginosis, overweight, obesity, therapy, remission.